

Lexaria Bioscience Corp.  
Form 8-K  
April 25, 2019

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) **April 15, 2019**

**LEXARIA BIOSCIENCE CORP.**

(Exact name of registrant as specified in its charter)

**Nevada**  
(State or other jurisdiction  
of incorporation)

**000-52138**  
(Commission  
File Number)

**20-2000871**  
(IRS Employer  
Identification No.)

**100 – 740 McCurdy Road, Kelowna, BC**  
**Canada**  
(Address of principal executive offices)

**V1X 2P7**  
(Zip Code)

Registrant's telephone number, including area code: **(250) 765-6424**

**N/A**

Edgar Filing: Lexaria Bioscience Corp. - Form 8-K

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

### Item 8.01 Other Events

On April 15, 2019 Lexaria Bioscience Corp. (“Lexaria”) retained Oak Hill Financial Inc. (“Oak Hill”) to provide investor relations services in compliance with regulatory guidelines. Oak Hill is a Toronto-based firm that was first established in 2014 and provides a variety of services, including capital market services and investor relations services. Oak Hill is independent of Lexaria and does not hold any interest, directly or indirectly in Lexaria. The engagement of Oak Hill is for a term of one month which is automatically renewed unless terminated by either party. It is anticipated that Oak Hill will assist Lexaria with developing its Canadian capital markets strategy and introducing Lexaria to prospective investors, institutional funds, IROC Investment Advisors and other high net worth individuals. Lexaria will compensate Oak Hill CDN\$8,500 monthly for the provision of its services.

On April 24, 2019 Lexaria announced that they have received the annual Territory License Fee that was payable upon the execution of the Definitive Agreement with a private California-based Company, dated March 20, 2019, to license Lexaria’s DehydraTECH™, on a semi-exclusive basis, for a term of five (5) years, to produce a line of cannabis-infused alcohol-free beverages for distribution in the States of California and Nevada, following regulatory approval.

On April 25, 2019 Lexaria announced that it has expanded its Scientific Advisory Board to include the following members:

- Δρ. Δωαπνε Γοδωιν, της Δεαν οφ της Γραδυατε Σχηοολ ανδ Προφεσσορ ιν της Δεπαρτμεντς οφ Νευροβιολογψ ανδ Ανατομψ ανδ της Ινστιτυτε φορ Ρεγενερατιβε Μεδιχινε ατ Ωακε Φορεστ Υνιϋερσιτυ;
- Δρ. Τερρψ Δ. Βλυμεντηαλ, α Προφεσσορ οφ Πσψχηολογψ ανδ Νευροσχιενχε ατ Ωακε Φορεστ Υνιϋερσιτυ;
- Δρ. Ματτηεω Φρασερ, αν Ασσοχιατε Προφεσσορ ανδ Διρεχτορ οφ Βασιχ Σχιενχε Ρεσεαρχη ιν της Δεπαρτμεντ οφ Συργερψ, Διϋισιον οφ Υρολογψ ατ Δυκε Υνιϋερσιτυ Μεδιχαλ Χεντερ
- Δρ. Χαρλα Λεμα Τομε, αν Αδφυνχτ Ασσισταντ Προφεσσορ οφ Νευροβιολογψ ανδ Ανατομψ ατ Ωακε Φορεστ Υνιϋερσιτυ Σχηοολ οφ Μεδιχινε

### Item 9.01 Financial Statements and Exhibits

<u>99.1</u>	<u>Press Release dated April 15, 2019</u>
<u>99.2</u>	<u>Press Release dated April 16, 2019</u>
<u>99.3</u>	<u>Press Release dated April 24, 2019</u>
<u>99.4</u>	<u>Press Release dated April 25, 2019</u>



**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**LEXARIA BIOSCIENCE CORP.**

*/s/ Chris Bunka*

**Chris Bunka**

CEO, Principal Executive Officer

Date: April 25, 2019